The market is pretty crappy to start this morning but let us see if the trend reverses. We have had a lot gap higher opens and then weakness the rest of the day, so perhaps this is a gap down and then strengthen sort of day. I do not think that is going to be […]
December 5 Biotech Update
Another day and another morning with an opening spike in large cap biotechs that was immediately sold. This is a disturbing pattern and one that needs to break if the sector is going to continue to move higher. Until we can get follow through on these opening moves, we are going to at best treat […]
November 6 Biotech Update- ASH Abstract Galore
So we have a massive dump of information today that I want to touch on but it is not possible to cover everything. I will do a series of quick hits to cover as much as I can and get it out as early as possible. I will then spend the next week or so […]
October 23 Bioech Update
The rebound is continuing with large caps continuing to lead but with good participation with the small caps, which is nice to see. It really is a little amazing to see how many V-shaped moves this market makes and how little memory it has day to day. In any case, I still think the path […]
September 24 Biotech Update
After a fairly weak start to the week, the sector seemed a little stronger this morning but the markets are teetering on a much larger correction. At this point, however, the markets may be oversold enough to get a near term bounce. The key is whether that bounce will be significant enough to push the […]
September 22 Biotech Update
The sector really seems bifurcated at this point. While the large caps have been pretty reliable winners the past couple of months, it seems like they are taking a break. Obviously, they are still close to their highs but more often than not they appear to struggle to gain and when they do the gains […]
September 15 Biotech Update
We have a very weak start to the week as biotech buyers appear to have stepped aside. At this point, I think it is safe to say that we are in the midst of a correction and now the question is a matter of degree. We should be approaching an area of support, so it […]
September 12 Biotech Update
Another day and another bit of weakness in the sector and market. The longer that we churn along at these levels the more it looks like stocks are resting for a continuation of the main trend (higher). It is not a high conviction view but unless the market breaks to the downside soon, it looks […]
September 8 Biotech Update
A slow start to a week, which I guess should have been expected given that last week was not exceptionally news filled. Without any real catalysts, it is likely the sector will track the broader market. The one advantage is that we have a series of investor conferences in September. While these usually do not […]
August 7 Biotech Update
A good start for the market but biotechs seemed to not be participating. While nothing in biotech stood out as particularly strong in the morning, it seems like small caps were slightly better than large caps. This was a trend I want to follow as it would mark a significant change in the sector as […]
July 14 Biotech Update
It was a mixed day in the market as the broader market seemed good but biotechs seemed more mixed. I am not sure these is much to make out of it as the key over the next couple of weeks will be earnings (at least for the larger biotechs) and then once we get through […]
July 9 Biotech Update
The market was better today but this is not surprising that we get a breather after the two day sell off. The key is what happens in the afternoon and tomorrow. In other words, we cannot know if this is simply a dead cat bounce before more selling or the end of a quick downdraft. […]
CAR-T in the spotlight: Cellectis
Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to $185M in milestones per product plus royalties on sales. Additionally, Pfizer has acquired a 10% stake in Cellectis. Pfizer has exclusive rights to develop 15 […]
July 1 Biotech Update
It was a good morning in the sector with some positive news and momentum, although we seemed to have faded a little. As I have been saying for awhile, I think the sector has a good shot to hit new all-time highs as long as the macro environment does not turn bearish. I do not […]
June 20 Biotech Update
I am glad that I did not miss too much yesterday but it is usually the case that a day or week off does not dramatically change your perspective. It was another good morning for biotechs and I still believe that we are going to make a run at the all-time sector highs if the […]
June 17 Biotech Update
The sector continues to do well and if the broader market correction holds off we may be making a move to all-time highs but I would remain cautious. In any case, the sector seems healthy at this point despite heading into the summer doldrums and a seasonally weak period. 1. So the one name I […]
June 16 Biotech Update- Good Data at EHA
A generally good start to the week for the sector with perhaps the good data out of EHA providing a nice early bump to sentiment. It seems to me that EHA was much more significant for small caps and biotech this year than ASCO despite getting a lot less play heading into the weekend. So […]
January 9- The Biotech Momentum Continues
It was a great day for biotechs despite a neutral to bearish macro drag. We not only had some great price action but we continued with the positive news. This is creating a nice bid under the sector and even the large caps that did not have much news per se moved higher. It is […]
November 12- EOD
Well, I think it was more of the same in the sector writ large with the biggest news obviously being SRPT, which I will touch on below. I was surprised to see the small caps hold up as well as they did on the news and that is a slight positive for the sector going […]
ASH 2013 Preview on rare blood disorders
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. Orphan diseases has been a key element in the bull market in biotech over the past 2-3 years. Consider that the market for hemophilia A treatments in 2011 was over $5 billion alone. Today’s preview will […]
